# Vesugen

Source: https://aminodesk.com/library/vesugen
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Vesugen is one of the Russian short peptides sold as bioregulators. It is marketed for blood vessel support. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people.

- **Legal lane:** not FDA-approved. Not eligible for pharmacy compounding. Sold as a research chemical.
- **Evidence grade:** D
- **What it is:** a short synthetic peptide
- **Established human dose:** none

## What it is

Vesugen is a short synthetic peptide.

It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell.

## What the evidence shows

Vesugen has been tested on human cells taken from the mouth, in a study of cell aging and bone formation presented by the developers' network. That is cell work, not a clinical result. We found no controlled human trial of Vesugen in the sources we reviewed.

For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded.

## Legal status

- Not FDA-approved for any use.
- Not eligible for pharmacy compounding, according to the research summary we read.
- Not one of the six peptides in the October 2026 policy.
- What is sold online is a research chemical.

## Reported dosing

**We do not publish a protocol for this compound.**

No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers.

## Safety

- No independent human safety data exists.
- A peptide this small is often assumed to be harmless. That assumption has not been tested.
- Products sold as research chemicals have no verified contents or sterility.

## Common questions

### What is Vesugen?

A Russian short peptide, one of the Khavinson bioregulators, sold for blood vessel support.

### Is Vesugen FDA-approved?

No. It is not approved and is not eligible for pharmacy compounding.

### Has Vesugen been tested in people?

We found no controlled human trial. The evidence is cell and animal work from the group that developed it.

## Sources

- [2019 conference abstract: Cartalax, Vesugen, Vilon and Epitalon on human oral-derived cells](https://khavinson.info/assets/files/pdf/2019-32_33.pdf)
- [Overview of the Khavinson short peptides and the tiers of evidence behind them](https://ipsnews.net/business/?p=248484)
- [The Peptide Column: bioregulator research summary and legal status](https://the-peptide-column.pages.dev/bioregulators)
- [Khavinson and Morozov, 2003: the 266-person elderly cohort (PubMed)](https://pubmed.ncbi.nlm.nih.gov/14523363/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
